Intermediate•8 min read
Atrial Fibrillation - CCS Case Guide
Key Takeaway: Atrial fibrillation is the most common sustained cardiac arrhythmia. CCS management requires determining hemodynamic stability, choosing rate versus rhythm control, calculating thromboembolic risk with CHA2DS2-VASc, initiating appropriate anticoagulation, and identifying reversible precipitants such as thyrotoxicosis, pulmonary embolism, or sepsis.
Atrial fibrillation is the most common sustained cardiac arrhythmia. CCS management requires determining hemodynamic stability, choosing rate versus rhythm control, calculating thromboembolic risk with CHA2DS2-VASc, initiating appropriate anticoagulation, and identifying reversible precipitants such as thyrotoxicosis, pulmonary embolism, or sepsis.
Recognizing the AFib Presentation
- History: Palpitations, dyspnea, lightheadedness, fatigue, exercise intolerance; may be asymptomatic and discovered incidentally
- Physical Exam: Irregularly irregular pulse, variable intensity of S1, absent a-waves in jugular venous pulse, possible signs of heart failure
- Vital Signs: Tachycardia (often 110-180 bpm with rapid ventricular response), blood pressure may be low if hemodynamically compromised
- ECG Findings: Absence of P waves, irregularly irregular R-R intervals, fibrillatory baseline, narrow QRS complex (unless aberrant conduction or WPW)
- Risk Factors: Hypertension, heart failure, valvular disease, obesity, obstructive sleep apnea, hyperthyroidism, alcohol use, advanced age
- Hemodynamic Assessment: Evaluate for hypotension, chest pain, altered mental status, or acute heart failure requiring emergent intervention
- Onset Determination: Duration of symptoms is critical: <48 hours may allow immediate cardioversion; >48 hours or unknown requires anticoagulation or TEE before cardioversion
Immediate Actions (First 5 Minutes)
These orders should be placed immediately — timing is scored:
Critical First Orders
- ✓ Obtain 12-lead ECG to confirm atrial fibrillation
- ✓ Assess hemodynamic stability (if unstable: emergent synchronized cardioversion)
- ✓ Establish IV access and continuous telemetry
- ✓ Start IV rate control: diltiazem 0.25 mg/kg bolus or metoprolol 5 mg IV
- ✓ Target heart rate <110 bpm at rest
- ✓ Calculate CHA2DS2-VASc score for anticoagulation decision
- ✓ Identify and treat precipitating causes (thyrotoxicosis, PE, sepsis, acute MI)
Complete Workup
After initial stabilization, complete the diagnostic workup:
- 12-lead ECG
- CBC (infection, anemia)
- BMP (electrolytes, renal function for drug dosing)
- TSH (hyperthyroidism as precipitant)
- Troponin (rule out acute coronary syndrome)
- BNP or NT-proBNP (assess for heart failure)
- Coagulation studies (PT/INR if considering anticoagulation)
- Chest X-ray (cardiomegaly, pulmonary edema, pneumonia)
- Echocardiogram (valvular disease, LV function, LA size)
- Transesophageal echocardiogram (TEE) if cardioversion planned and AFib duration >48 hours or unknown
- Hepatic function panel (baseline before anticoagulation or antiarrhythmic)
Treatment
Rate Control
- IV diltiazem bolus 0.25 mg/kg, then infusion 5-15 mg/hr
- IV metoprolol 5 mg every 5 minutes (up to 3 doses), then oral metoprolol
- Oral diltiazem or metoprolol for long-term rate control
- Digoxin for rate control in heart failure with reduced EF (avoid as monotherapy)
- Target resting heart rate <110 bpm (lenient control) or <80 bpm (strict control)
Rhythm Control
- Consider for symptomatic patients despite rate control, younger patients, or first episode
- Flecainide or propafenone for structurally normal hearts
- Amiodarone for structural heart disease or heart failure
- Electrical cardioversion (synchronized) if hemodynamically unstable or if pharmacologic cardioversion fails
- Anticoagulate for ≥3 weeks before elective cardioversion if AFib >48 hours (or TEE to exclude thrombus)
Anticoagulation
- CHA2DS2-VASc ≥2 in men or ≥3 in women: oral anticoagulation indicated
- DOAC preferred over warfarin: apixaban 5 mg BID, rivaroxaban 20 mg daily, or dabigatran 150 mg BID
- Warfarin (target INR 2-3) if mechanical valve or moderate-to-severe mitral stenosis
- Assess bleeding risk with HAS-BLED score
- Adjust DOAC dosing for renal function and age
Upstream Therapy and Referral
- Treat underlying cause (thyroid disease, sleep apnea, valvular disease, alcohol)
- Cardiology referral for catheter ablation consideration
- Left atrial appendage occlusion (Watchman) for patients who cannot tolerate anticoagulation
Common Pitfalls
Scoring Tip: These are the most commonly missed actions for AFib cases.
- Using rate-controlling agents (diltiazem, beta-blockers) in WPW with AFib (can cause VF; use procainamide or cardioversion)
- Cardioverting AFib of >48 hours duration without anticoagulation or TEE
- Failing to calculate CHA2DS2-VASc and initiate anticoagulation when indicated
- Not checking TSH to rule out hyperthyroidism as a reversible cause
- Using flecainide or propafenone in patients with structural heart disease
- Prescribing aspirin alone for stroke prevention (insufficient in most patients)
Disposition
- Discharge with rate control medication and anticoagulation if stable and rate controlled
- Admit for persistent rapid ventricular response despite initial treatment
- Admit for new-onset AFib with hemodynamic instability, heart failure, or acute coronary syndrome
- Cardiology follow-up within 1-2 weeks for outpatient management and rhythm strategy discussion
Key Orders Checklist
- ☐ 12-lead ECG
- ☐ Continuous telemetry
- ☐ IV diltiazem or metoprolol
- ☐ TSH level
- ☐ Troponin
- ☐ BNP or NT-proBNP
- ☐ Echocardiogram
- ☐ CHA2DS2-VASc calculation
- ☐ Apixaban or rivaroxaban initiation
- ☐ Chest X-ray
- ☐ BMP and hepatic panel
Practice AFib Cases
Apply these strategies with our realistic AFib simulations and get instant AI feedback.
Try a Free Case